Stemline Therapeutics is based out of New York. Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas.Whalewisdom has at least 73 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2012-01-17. The notice included securities offered of Debt,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
Contact Info
Contact information is taken directly from publicly disclosed SEC filings.
STEMLINE THERAPEUTICS INC750 LEXINGTON AVENUE
NEW YORK NY 10022
Business Phone: 212-831-1111
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS
2834-PHARMACEUTICAL PREPARATIONS